Network origin in Kim Clarke first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Holding Company | Biotechnology | 22 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Kim Clarke via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ABIOMED, INC. | Medical Specialties | Investor Relations Contact | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BOSTON SCIENTIFIC CORPORATION | Medical Specialties | Investor Relations Contact | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CVS HEALTH CORPORATION | Drugstore Chains | Investor Relations Contact | |
Cowen & Co. LLC
 Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Investment Banks/Brokers | Corporate Officer/Principal | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member | |
| JPMORGAN CHASE & CO. | Major Banks | Corporate Officer/Principal | |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| NVN LIQUIDATION, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ASTERIAS BIOTHERAPEUTICS INC | Biotechnology | Director/Board Member | |
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC. | Medical Specialties | Director/Board Member | |
| MALIN CORPORATION PLC | Biotechnology | Chief Executive Officer Founder Director/Board Member | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree | |
| Stanford University | College/University | Masters Business Admin Undergraduate Degree | |
| GW PHARMACEUTICALS PLC | Pharmaceuticals: Major | Sales & Marketing | |
| OCERA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
| St. Joseph's University | College/University | Undergraduate Degree | |
| University of California, Davis | College/University | Doctorate Degree | |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | General Government | Corporate Officer/Principal | |
| THERMO FISHER SCIENTIFIC | Medical Specialties | Corporate Officer/Principal Director of Finance/CFO | |
Manhattan Institute For Policy Research, Inc.
 Manhattan Institute For Policy Research, Inc. Miscellaneous Commercial ServicesCommercial Services Manhattan Institute For Policy Research, Inc. develops and disseminate new ideas for greater economic choice and individual responsibility. It focuses on economic growth, education, energy and environment, health care, legal reform, public sector, race and urban policy. The company was founded by Antony Fisher and William J. Casey in 1977 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BAUSCH HEALTH COMPANIES INC. | Pharmaceuticals: Other | Director/Board Member | |
| SERES THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| ONCOCYTE CORPORATION | Biotechnology | Director/Board Member | |
| National Comprehensive Cancer Network Foundation | Director/Board Member | ||
| The Leonard N Stern School of Business | College/University | Masters Business Admin | |
| Georgetown University School of Medicine | College/University | Doctorate Degree | |
| Samaritan Health Initiatives, Inc. | Founder | ||
Brandon Point Industries Ltd.
 Brandon Point Industries Ltd. Medical/Nursing ServicesHealth Services Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland. | Medical/Nursing Services | Founder Director/Board Member | |
| The University of Utah Health Sciences Center | Corporate Officer/Principal | ||
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Malin Life Sciences Holdings Ltd.
 Malin Life Sciences Holdings Ltd. Financial ConglomeratesFinance Part of Malin Corp. Plc, Malin Life Sciences Holdings Ltd. functions as an investment holding Irish company. The company is based in Dublin, Ireland. The CEO of the company is George Kelly Martin. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
Peel Therapeutics, Inc.
 Peel Therapeutics, Inc. BiotechnologyHealth Technology Peel Therapeutics, Inc. engages as pre-clinical stage biotech that is strategically positioned at the intersection of nature and technology. The company is founded by Joshua Schiffman and Avi Schroeder in 2015 and is headquartered in Salt Lake City, UT. | Biotechnology | Director/Board Member | |
| FSD PHARMA INC. | Biotechnology | Chief Executive Officer | |
| FORTREA HOLDINGS INC. | Miscellaneous Commercial Services | Director/Board Member | |
| TRISALUS LIFE SCIENCES, INC. | Medical Specialties | Director/Board Member Director of Finance/CFO Director/Board Member | |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
 Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC). | Investment Banks/Brokers | Sales & Marketing | |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| United States | 42 |
| Ireland | 5 |
| United Kingdom | 3 |
| Sweden | 2 |
| Switzerland | 2 |
Sectoral
| Health Technology | 29 |
| Consumer Services | 8 |
| Finance | 5 |
| Commercial Services | 4 |
| Producer Manufacturing | 2 |
Operational
| Director/Board Member | 139 |
| Independent Dir/Board Member | 51 |
| Corporate Officer/Principal | 46 |
| Chief Executive Officer | 17 |
| Undergraduate Degree | 17 |
Most connected contacts
| Insiders | |
|---|---|
| Andrew von Eschenbach | 33 |
| Jean-Pierre Garnier | 28 |
| Owen Hughes | 23 |
| Sean Murphy | 22 |
| George Martin | 21 |
| Catherine Friedman | 20 |
| Jennifer Jarrett | 18 |
| Willard Dere | 16 |
| A. Sanders | 11 |
| James Chopas | 10 |
| Mark Conley | 10 |
| Laura Furmanski | 10 |
| Susan Vissers Lisa | 9 |
| Travis Wilson | 9 |
| Scott Briggs | 5 |
- Stock Market
- Insiders
- Kim Clarke
- Company connections